Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | +32.89% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.20 | N/A | +32.89% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing their commitment to pipeline development. They did not provide any forward guidance.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its pipeline despite current challenges.
Nektar Therapeutics reported a loss of $0.20 per share, which was better than expected, but the lack of revenue details and guidance contributed to a stock decline of nearly 5%. Investors may be concerned about the company's future performance given the absence of specific guidance and the overall market conditions. The stock reaction reflects uncertainty among investors about the company's direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STIFEL FINL CORP
Nov 5, 2007